Its own table labels the theoretical synergy unproven at the population level, which is why it avoids endorsing the pairing
While these drugs are highly effective for weight loss and glycemic control, they are associated with gastrointestinal issues such as nausea, vomiting, and diarrhea, which can lead to treatment discontinuation among some patients For instance, clinical data and patient reports have shown that adverse events are particularly common during the early stages of treatment with drugs such as semaglutide and tirzepatide, prompting careful dose titration and medical supervision, which may not be feasible for all patients or healthcare settings Addressing these side effect concerns through better patient education, physician training, and next-generation formulations with reduced tolerability issues is crucial to improving long-term adherence and treatment outcomes
Slowed gastric emptying: Semaglutide slows the rate at which food moves from the stomach into the small intestine
adults (65%) said in a February 2024 Pew Research Center survey that willpower alone is usually not enough for most people to lose weight and keep it off
Research has identified three specific nutrients as the strongest stimulators
